|
Risk of pancreatitis and pancreatic cancer with sitagliptin and exenatide highlighted. |
 |
 |
|
Science Blog: Researchers from the Larry L. Hillblom Islet Research Center at UCLA examined the U.S. Food and Drug Administration’s database for adverse events reported between 2004 and 2009 among patients using the drugs sitagliptin and exenatide. They found a six-fold increase in the odds ratio for reported cases of pancreatitis with these drugs, compared with four other diabetes therapies they used as controls. They also found that patients who took the two drugs were more likely to have developed pancreatic cancer than those who were treated with the other therapies. The study is published in the journal Gastroenterology.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
